Recurrent Angina: New Tools for an Old Problem

Slides:



Advertisements
Similar presentations
Summary Prepared by Melvyn Rubenfire, MD
Advertisements

Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Pablo M. Bedano M.D. Community Regional Cancer Care.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Myocardial Ischemia Redefined: Optimal Care in CAD.
Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Silent Ischemia STABLE CAD
Ongoing Trials in Managing Myocardial Ischemia. MERLIN-TIMI 36: Study design IV/oral ranolazinePlacebo Patients with non-ST elevation ACS treated with.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
ACC/AHA 2006 guidelines on the management of PAD.
4S: Scandinavian Simvastatin Survival Study
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
STICH CABG Objective To determine whether surgery plus medical management or medical management alone improve outcomes in CABG patients Study Design 1212.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Total Occlusion Study of Canada (TOSCA-2) Trial
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Copyright © 2009 American Medical Association. All rights reserved.
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
Clinical need for determination of vulnerable plaques
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Scandinavian Simvastatin Survival Study (4S)
Trends in Coronary Procedures per 1000 Medicare Beneficiaries
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
Preventing Thrombotic Complications in ACS: State of the Art
Statin Selection in the Elderly
Atrial Fibrillation and PCI
Acute Heart Failure.
Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.
How and When to Decide on Revascularization in Stable Ischemic Heart Disease.
Prevalence of statin and beta-blocker use by clinical presentation
Antiplatelet Therapy and Secondary Prevention
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Considerations for Percutaneous Coronary Intervention (PCI)
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Section 5: Intervention and drug therapy
Tackling CV Risk in T2DM.
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
The European Society of Cardiology Presented by RJ De Winter
Duration of Dual Antiplatelet Therapy
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies
Typical Patient Presentation
Antithrombotics in Arterial Disease: Focus on Coronary Disease
LRC-CPPT and MRFIT Content Points:
Factor Xa Inhibitors in Coronary Artery Disease
Adjunctive Therapies in the Treatment of Acute Coronary Syndromes
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
The American College of Cardiology Presented by Dr. A. Abazid
FIELD: Primary outcome
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Section C: Clinical trial update: Oral antiplatelet therapy
Presentation transcript:

Recurrent Angina: New Tools for an Old Problem

Angina in the United States: Morbidity and Age-Related Issues

Nonflow-Limiting Lesions Are the Principal Progenitors of Most Acute MI Events

Meta-analysis of PCI vs Medical Therapy Trials: Death and Nonfatal MI Outcomes

Chronic Stable Coronary Artery Disease Performance Measurement Set

75-Year-Old Woman With T2DM

75-Year-Old Woman (cont)

75-Year-Old Woman (cont): Medications

Reductions in A1c Seen With Ranolazine Use in Randomized Trials

53-Year-Old Woman

53-Year-Old Woman (cont)

53-Year-Old Woman (cont): Family History

53-Year-Old Woman (cont): Medications and Lab Results

53-Year-Old Woman (cont): Clinical Decision Point

Microvascular Coronary Dysfunction in Women With Angina and Ischemia, but no Obstructive CAD

WISE: 5-Year Rates of CV Outcomes in Symptomatic Women With No CAD vs Nonobstructive CAD

Nonobstructive CAD and All-Cause Mortality

Plan of Care for Chronic Stable Coronary Artery Disease

53-Year-Old Woman (cont): Clinical Decision Point

DASI: Measures Functional Capacity and Assesses Aspects of Quality of Life

Program Summary

Abbreviations

Abbreviations